FindTrial
Sign In

A Mechanistic Study of Anti-Pulmonary Fibrosis Decoction in the Treatment of Idiopathic Pulmonary Interstitial Fibrosis Based on Metabolomics: A Single-Center Randomized Controlled Trial

Mechanism Study of Antifibrotic Decoction for the Treatment of Idiopathic Pulmonary Fibrosis Based on Metabolomics and Network Pharmacology Approaches

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000305
Enrollment
Unknown
Registered
2026-02-09
Start date
2023-01-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

Research Group:The treatment group received anti-pulmonary-fibrosis decoction intervention on the basis of routine treatment, administered once daily, divided into two doses, once in the morning and o
Control Group:Conventional treatment

Sponsors

Xuzhou City Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) According to the diagnostic criteria in the "2018 Evidence-Based Diagnostic Guidelines for Idiopathic Pulmonary Fibrosis" jointly developed by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Society; (2) Age =40 years old, =85 years old; (3) IPF patients in a stable phase at the time of enrollment in the trial.

Exclusion criteria

Exclusion criteria: (1) Use of prednisone exceeding 10 mg/day (or equivalent dose of other glucocorticoids) within 2 weeks prior to enrollment; (2) Use of immunosuppressive agents within 1 month prior to enrollment; (3) Participation in other drug trials within 3 months prior to enrollment; (4) Severe cardiac dysfunction (New York Heart Association functional classification Class III or above), severe hepatic or renal impairment (serum AST, ALT, BUN, or creatinine levels exceeding twice the upper limit of normal); (5) Patients with concurrent malignant tumors; (6) Patients with severe infections; (7) Pregnant or breastfeeding women; (8) Patients with mental disorders or cognitive impairments; (9) Patients unwilling to cooperate or unable to complete follow-up; (10) Patients with a known allergy to the investigational drug.

Design outcomes

Primary

MeasureTime frame
Serum metabolomics indices;Pulmonary Function (FVC, FVC%, FEV1, FEV1%, DLCO%);—

Secondary

MeasureTime frame
Clinical Symptoms and Signs Scoring;Saint George's Respiratory Questionnaire (SGRQ);6-Minute Walk Test (6MWT);—

Countries

China

Contacts

Public ContactZhao Ying

Xuzhou City Traditional Chinese Medicine Hospital

njmuzy@126.com18205211881

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Mar 14, 2026